Pridopidine
- Generic Name
- Pridopidine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C15H23NO2S
- CAS Number
- 346688-38-8
- Unique Ingredient Identifier
- HD4TW8S2VK
- Background
Pridopidine has been used in trials studying the treatment of Huntington's Disease.
- Associated Conditions
- -
- Associated Therapies
- -
Pridopidine in Amyotrophic Lateral Sclerosis (EAP 2)
- Conditions
- First Posted Date
- 2023-10-06
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Prilenia
- Registration Number
- NCT06069934
- Locations
- ๐บ๐ธ
University of Alabama at Birmingham, Birmingham, Alabama, United States
๐บ๐ธBarrow Neurological Institute, Phoenix, Arizona, United States
๐บ๐ธUniversity of California, San Diego Health, La Jolla, California, United States
HEALEY ALS Platform Trial - Regimen D Pridopidine
- Conditions
- Interventions
- First Posted Date
- 2020-11-04
- Last Posted Date
- 2023-08-23
- Lead Sponsor
- Merit E. Cudkowicz, MD
- Target Recruit Count
- 163
- Registration Number
- NCT04615923
- Locations
- ๐บ๐ธ
Healey Center for ALS at Mass General, Boston, Massachusetts, United States
PRidopidine's Outcome On Function in Huntington Disease, PROOF- HD
- Conditions
- Interventions
- First Posted Date
- 2020-09-21
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Prilenia
- Target Recruit Count
- 499
- Registration Number
- NCT04556656
- Locations
- ๐ฆ๐น
Prilenia Investigational site (Site 291), Innsbruck, Austria
๐ซ๐ทPrilenia Investigational Site (Site 385), Lille, France
๐ซ๐ทPrilenia Investigational Site (Site 384), Marseille, France
HEALEY ALS Platform Trial - Master Protocol
- Conditions
- Interventions
- First Posted Date
- 2020-03-05
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Merit E. Cudkowicz, MD
- Target Recruit Count
- 1500
- Registration Number
- NCT04297683
- Locations
- ๐บ๐ธ
Neurology Associates, P.C./Somnos Clinical Research, Lincoln, Nebraska, United States
๐บ๐ธKaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
๐บ๐ธJohns Hopkins University, Baltimore, Maryland, United States
A Study to Assess the Safety and Effectiveness of Pridopidine Compared to Placebo in the Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson's Disease
- First Posted Date
- 2019-04-22
- Last Posted Date
- 2022-07-01
- Lead Sponsor
- Prilenia
- Target Recruit Count
- 23
- Registration Number
- NCT03922711
- Locations
- ๐บ๐ธ
Prilenia Investigational Site (Site 115), Scottsdale, Arizona, United States
๐บ๐ธPrilenia Investigational Site (Site 122), Sunrise, Florida, United States
๐บ๐ธPrilenia Investigational Site (Stie 142), Torrance, California, United States
A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease
- First Posted Date
- 2015-07-10
- Last Posted Date
- 2021-09-17
- Lead Sponsor
- Prilenia
- Target Recruit Count
- 248
- Registration Number
- NCT02494778
- Locations
- ๐บ๐ธ
Teva Investigational Site 12204, Los Angeles, California, United States
๐บ๐ธTeva Investigational Site 12206, Baltimore, Maryland, United States
๐บ๐ธTeva Investigational Site 12200, Manhasset, New York, United States
A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease
- First Posted Date
- 2013-12-10
- Last Posted Date
- 2021-07-19
- Lead Sponsor
- Prilenia
- Target Recruit Count
- 408
- Registration Number
- NCT02006472
- Locations
- ๐บ๐ธ
Investigational Site 12200, Manhasset, New York, United States
๐บ๐ธInvestigational Site 12209, Pittsburgh, Pennsylvania, United States
๐จ๐ฆInvestigational Site 11036, Toronto, Ontario, Canada
Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease
- First Posted Date
- 2011-03-02
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Prilenia
- Target Recruit Count
- 134
- Registration Number
- NCT01306929
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.